MYCN and neuroblastoma: The International Neuroblastoma Risk Group (INRG) provides a consensus pretreatment classification scheme for risk-stratified therapy according to the stage, age, histology, MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)) status, and other genetic aberrations of NBL patients [2].